Chinese Japanese Germany Korea
ChemicalBook >> CAS DataBase List >>Deucravacitinib

Deucravacitinib

Deucravacitinib Structure
Deucravacitinib structure
CAS No.
1609392-27-9
Chemical Name:
Deucravacitinib
Synonyms
Deucravacitinib;6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide;Unii-N0A21N6rau;Tyk2-IN-4;Decavatinib;Deucravacitinb;BMS-986165 API;Deuterium seletinib;BMS-986165, >98% (HPLC);Deucravacitinib (TYK2-IN-4
CBNumber:
CB74808663
Molecular Formula:
C20H22N8O3
Molecular Weight:
422.45
MDL Number:
MOL File:
1609392-27-9.mol
MSDS File:
SDS
TDS File:
TDS
Last updated:2026-07-27 17:00:41
Request For Quotation

Deucravacitinib Properties

storage temp. Store at -20°C
solubility DMF: 1 mg/ml; DMSO: 1 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml
form A crystalline solid
color Off-white to light yellow
InChIKey BZZKEPGENYLQSC-UHFFFAOYSA-N
SMILES O(C1C(=CC=CC=1C1=NN(C)C=N1)NC1C=C(NC(C2CC2)=O)N=NC=1C(=O)NC([H])([H])[H])C
FDA UNII N0A21N6RAU

SAFETY

Risk and Safety Statements

Symbol(GHS)  Health Hazard (GHS08)
GHS08
Signal word  Danger
Hazard statements  H361f-H372
Precautionary statements  P260-P264-P270-P314-P501

Deucravacitinib price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 33524 BMS 986165 ≥98% 1609392-27-9 1mg $49 2026-04-30 Buy
Cayman Chemical 33524 BMS 986165 ≥98% 1609392-27-9 5mg $223 2026-04-30 Buy
Cayman Chemical 33524 BMS 986165 ≥98% 1609392-27-9 10mg $354 2026-04-30 Buy
Cayman Chemical 33524 BMS 986165 ≥98% 1609392-27-9 25mg $587 2026-04-30 Buy
Biosynth JPC39227 BMS-986165 1609392-27-9 250mg $362.5 2026-06-04 Buy
Product number Packaging Price Buy
33524 1mg $49 Buy
33524 5mg $223 Buy
33524 10mg $354 Buy
33524 25mg $587 Buy
JPC39227 250mg $362.5 Buy

Deucravacitinib Chemical Properties,Uses,Production

Uses

BMS-986165 is a novel oral selective TYK2 inhibitor with a unique mechanism of action that is expected to provide a promising oral option to help patients effectively manage their psoriasis.

Description

Deucravacitinib (trade name Sotykto) is a first-in-class tyrosine kinase 2 (TYK2) inhibitor recently approved for the treatment of moderate to severe plaque psoriasis. Psoriasis is a chronic inflammatory skin disease characterized by the formation of red patches and scaling on the skin. Discovered by Bristol Myers Squibb (BMS), deuterated colestitinib, also known as BMS-986165, is the first JAK inhibitor containing deuterium and the first approved selective TYK2 inhibitor, showing more than 50,000-fold selectivity over JAK1, JAK2 and JAK3.

Uses

Deucravacitinib is a tyrosine kinase 2 inhibitor which can be useful in the treatment of systemic lupus erythematosus.

General Description

Deucravacitinib, a highly selective allosteric TYK2 inhibitor, received its first approval from the FDA in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy protein and lipid kinases and pseudokinases with the exception of BMPR2 (IC50 = 193 nM) and JAK1 JH2 pseudokinase domain (IC50 = 1 nM). Despite its potent affinity for JAK1 JH2, deucravacitinib elicited low functional activity in a JAK1/JAK3-dependent IL-2 stimulated cellular assay. BMS-986202 displays >10,000-fold selectivity for TYK2 JH2 over a diverse panel of 273 kinases and pseudokinases that include JAK family members. Like deucravacitinib, its high binding affinity to JAK1 JH2 (IC50 = 7.8 nM) did not translate to functional activity in the cellular assay.

Pharmacokinetics

The crystalline free base form of deucravacitinib exhibited poor aqueous solubility (5.2 μg/mL), which was still acceptable for preclinical studies. It showed moderate half-lives of 45 h across species (mouse, dog, and monkey). Excellent exposures and high bioavailability (F > 85%) in mice, dogs, and monkeys were obtained from oral pharmacokinetic studies at a 10 mpk dose. Following oral administration of deucravacitinib, the major metabolite in human plasma was the cyclopropyl carboxamide hydrolytic cleavage product 4 (6-amino-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-methylpyridazine-3-carboxamide).

Synthesis

Lewis acid-mediated SNAr reaction of pyridazine 15.12 and aniline 15.7 gave 15.13 in 95% yield with excellent regioselectivity (∼185:1 15.13:15.14). Although an unconventional compound, 15.13 was isolated as a Zn-dicarboxylate due to its good solubility, ease of crystallization and isolation. The aryl pyridazine 15.13 then formed a C-N bond with amide 15.15 under Pd catalysis to afford the penultimate carboxylate 15.16 in 94% yield. Trideuterated methylamides were generated under standard amide coupling conditions. Deucravacitinib was prepared in 75% yield by crystallization in NMP and i-PrOH.

IC 50

Tyk2 JH2: 0.2 nM (IC50); JAK1 JH2: 1 nM (IC50); IL-12; IL-23

Deucravacitinib synthesis

6228-73-5
1609394-23-1
1609392-27-9
Synthesis of Deucravacitinib from Cyclopropanecarboxamide and BMS-986165 Related Compound 6

Deucravacitinib Preparation Products And Raw materials

Raw materials

2-Methoxy-3-nitrobenzamide BMS-986165 Related Compound 6 2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)aniline 3-(2-methoxy-3-nitrophenyl)-1-methyl-1H-1,2,4-triazole 3-(2-methoxy-3-nitrophenyl)-1H-1,2,4-triazole
Methyl-2-methoxy-3-nitrobenzoate Methyl-d3-amine hydrochloride ethyl 4,6-dihydroxypyridazine-3-carboxylate Ethyl 4,6-dichloropyrridazine-3-carboxylate Methyl 2-hydroxy-3-nitrobenzoate
Cyclopropanecarboxamide 3-Nitrosalicylic acid

1of3

Preparation Products

Deucravacitinib Suppliers

Global( 251)Suppliers
Supplier Tel Email Country ProdList Advantage
Jinan XuanDe Chemical Co., Ltd. 0531-88803958 19862127196 zhangxu@shiningpharm.com China 201 58
ShangHai Caerulum Pharma Discovery Co., Ltd. 18149758185 18149758185 sales-cpd@caerulumpharma.com China 3493 58
Shanghai Hope Chem Co., Ltd.， +21-18501659228 18501659228 info@hope-chem.com China 538 55
Cangzhou Kangrui Medical Technology Co., LTD 18632776803 cangzhoukangrui@126.com;355803330@qq.com China 676 58
Jinan Dexinjia Bio&Tech Co., Ltd 0531-82375880 15098789112 3845379039@qq.com China 1459 58
Cangzhou Enke Pharma Tech Co.,ltd. 0317-5106596 15533709196 1154424302@qq.com China 2502 58
CHANGZHOU PHARMACEUTICAL FACTORY 0519-88821493 18915891730 shm@czpharma.com China 176 58
Cangzhou Nianke Pharmaceutical Technology Co., Ltd. 18958645613 15076704415 3190065639@qq.com China 678 58
Shandong utilizing biological technology co., LTD 18669728830 15966937598 3407650895@qq.com China 5169 58
Chembest Research Laboratories Limited 021-20908456 sales@BioChemBest.com China 5996 61
Supplier Advantage
Jinan XuanDe Chemical Co., Ltd. 58
ShangHai Caerulum Pharma Discovery Co., Ltd. 58
Shanghai Hope Chem Co., Ltd.， 55
Cangzhou Kangrui Medical Technology Co., LTD 58
Jinan Dexinjia Bio&Tech Co., Ltd 58
Cangzhou Enke Pharma Tech Co.,ltd. 58
CHANGZHOU PHARMACEUTICAL FACTORY 58
Cangzhou Nianke Pharmaceutical Technology Co., Ltd. 58
Shandong utilizing biological technology co., LTD 58
Chembest Research Laboratories Limited 61

View Lastest Price from Deucravacitinib manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Deucravacitinib pictures 2026-09-11 Deucravacitinib
1609392-27-9
 1g More Than 99% 50kg/Month BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
Deucravacitinib BMS-986165 pictures 2026-09-11 Deucravacitinib BMS-986165
1609392-27-9
 1g More Than 99% 100kg/Month BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
BMS-986165 pictures 2026-08-20 BMS-986165
1609392-27-9
 $1.10 1g 99.0% Min 100 Tons Dideu Industries Group Limited
  • Deucravacitinib pictures
  • Deucravacitinib
    1609392-27-9
  • $0.00
  • More Than 99%
  • BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
  • BMS-986165 pictures
  • BMS-986165
    1609392-27-9
  • $1.10
  • 99.0% Min
  • Dideu Industries Group Limited

Deucravacitinib Spectrum

BMS-986165(1609392-27-9)1HNMR

1609392-27-9(Deucravacitinib)Related Search:

BMS-345541 BMS-986142 BMS-911543 CEP 33779 Tofacitinib citrate
IL-2 PROTEIN, MOUSE

1of2

Tyk2-IN-4 TYK2-IN-4;BMS986165;BMS-986165;BMS 986165 Deucravacitinib Deucravacitinib(BMS986165) Deucravacitinib (TYK2-IN-4 6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H?)methylpyridazine-3-carboxamide DeucravacitinibQ: What is Deucravacitinib Q: What is the CAS Number of Deucravacitinib Janus kinase,inhibit,JAK,Interleukin Related,Interferon-alpha/beta receptor,BMS 986165,Interferon-α/β receptor,IFNAR,Inhibitor,Deucravacitinib,BMS986165 6-[(Cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]-N-(methyl-d3)-3-pyridazinecarboxamide 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Deucravacitinb BMS-986165 API BMS-986165, >98% (HPLC) Deucravacitinib, 10 mM in DMSO Decavatinib Deuterium seletinib 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide - [AC79859] 6-Cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H3)methylpyridazine-3-carboxamide 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide Unii-N0A21N6rau 6-[(Cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]-N-(methyl-d3)-3-pyridazinecarboxamide (ACI) 1609392-27-9 API APIS API